Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 34

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 34
---
 different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from Keystone in this offering as a result of future sales made by us to Keystone at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to Keystone under the Keystone Purchase Agreements, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangements with Keystone may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. 11 We are engaged in multiple transactions and offerings of our securities. Future resales and/or issuances of shares of Common Stock, including pursuant to this prospectus, or the perception that such sales may occur, may cause the market price of our shares to drop significantly. In February 2024, November 2024, July 2025 and on November 26, 2025, we entered into the Keystone Purchase Agreements, pursuant to which Keystone shall purchase from us up to an aggregate of $25.0 million of shares of Common Stock, upon the terms and subject to the conditions and limitations set forth in the Keystone Purchase Agreements. We have issued an aggregate of 992 Keystone Commitment Shares to Keystone as consideration for its execution and delivery of the Keystone Purchase Agreements. The shares of our Common Stock that may be issued under the Keystone Purchase Agreements may be sold by us to Keystone at our discretion from time to time from the applicable Keystone Commencement Date until the earliest to occur of (i) the 36-month anniversary of the effective date of the applicable Registration Statement, (ii) the date on which Keystone has purchased the Keystone Commitment Amount pursuant to the Keystone Purchase Agreements, (iii) the date on which our Common Stock fails to be listed or quoted on Nasdaq or any successor Eligible Market (as defined in the Keystone Purchase Agreements), and (iv) the date on which, pursuant to or within the meaning of any bankruptcy law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit of our creditors. The purchase price for shares of our Common Stock that we may sell to Keystone under the Keystone Purchase Agreements will fluctuate based on the trading price of shares of our Common Stock. Depending on market